Natera ESMO presentations will feature 20 abstracts at the European Society for Medical Oncology Annual Congress in Madrid on October 23–26, 2026. Announcing the program on October 18, Natera said the research will include its Signatera Genome with Phased and Structural Variants test, with studies examining cancer recurrence monitoring and treatment decisions.
Key Takeaways
- Natera and its collaborators plan to present 20 abstracts, including four rapid oral presentations.
- The program includes research on Signatera Genome’s detection sensitivity and serial cancer monitoring.
- Study summaries describe associations with recurrence risk and changes in treatment plans, not proof of improved survival.
Table of Contents
- Natera ESMO presentations focus on cancer monitoring
- Studies examine recurrence and treatment changes
- Broader portfolio also gets a research showcase
- Conclusion
Natera ESMO presentations focus on cancer monitoring
Natera’s ESMO 2026 presentation program spans multiple tumor types and treatment settings. The company will highlight molecular residual disease, or MRD, testing using circulating tumor DNA, alongside other technologies in its oncology diagnostics portfolio.
For Signatera Genome with Phased and Structural Variants, Natera reported an analytical limit of detection, designated LOD95, below one part per million. It separately reported detection observed significantly below one part per 10 million. These are distinct measures: the lower observed detection level should not be treated as interchangeable with the stated LOD95.
| Item | Details |
|---|---|
| HER2-positive metastatic breast cancer | An analysis of exceptional responders found 81% had sustained MRD negativity during serial monitoring. |
| Complementary genomic profiling | A cohort of 50 patients across 10 tumor types identified clinically relevant biomarkers in 18 patients. |
| Breast and colorectal cancer surveillance | A retrospective analysis associated serial Signatera negativity with an extremely low two-year recurrence risk. |
Studies examine recurrence and treatment changes
In the ICONIC gastroesophageal cancer trial, Natera said MRD clearance during treatment before surgery was strongly associated with lower recurrence risk and a favorable pathological response. Signatera Genome detected all evaluable recurrences during surveillance, with a median lead time of more than 7.3 months over standard imaging. The announcement did not specify the number of evaluable recurrences.
In the phase III SAGITTARIUS colon cancer trial, Signatera results influenced a change to clinicians’ pre-planned treatment for one in three patients. Among those whose plans changed, 87% had treatment de-escalated based on negative MRD results.
Those findings address different questions: ICONIC examines recurrence detection and risk, while the SAGITTARIUS analysis examines how test results influence treatment choices. Neither summary alone establishes that test-guided treatment improves survival.
Broader portfolio also gets a research showcase
The program extends beyond Signatera Genome. A phase II lung cancer trial evaluated MRD clearance using Natera’s Clarity assay with phased variant technology. Another study paired Signatera monitoring with blood-based comprehensive genomic profiling to identify clinically relevant biomarkers.
The presentations provide a scheduled research update for Natera’s oncology business. They are not an earnings release or revenue forecast, and the announcement does not quantify a financial effect from the findings.
Conclusion
The next scheduled milestone is the October 23–26 congress, where the presentations will provide more detail on study populations, methods and outcomes behind Natera’s announced findings.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
